Innovation Pharmaceuticals Completes Dosing in Phase 1 Trial for New Oral Ulcerative Colitis Drug

Ads

You May Also Like

Aptose to Participate in Upcoming Investor Conferences

SAN DIEGO and TORONTO, March 02, 2017 (GLOBE NEWSWIRE) -- Aptose Biosciences Inc. (NASDAQ:APTO) ...

Biocartis Group NV: Idylla(TM) Respiratory (IFV-RSV) Panel receives 510(k) clearance by US FDA

PRESS RELEASE: 5 September 2017, 07:00 CEST Idylla(TM) Respiratory (IFV-RSV) Panel receives 510(k) clearance by ...